Theravance Biopharma is a biopharmaceutical company focused on developing respiratory medicines primarily for the US and European markets. Its flagship product, YUPELRI, is a once-daily treatment for chronic obstructive pulmonary disease (COPD). The company is also working on Ampreloxetine for neurogenic orthostatic hypotension and TRELEGY for COPD and asthma. Founded in 2013 and headquartered in South San Francisco, California, Theravance Biopharma has partnerships with Pfizer and Viatris for advancing its research and development efforts.